Research outputs

@article{Debourdeau2026,

title = {Intravitreal faricimab in patients with nAMD: French data from the Fight Retinal Blindness! Registry},

author = {Eloi Debourdeau and Deborah Harboun and Pierre-Henry Gabrielle and Yohei Hashimoto and Chloe Chamard and Frederic Michon and Benjamin Wolff and Heloise Torres-Villaros and Audrey Giocanti-Auregan and Mark Gillies and Catherine Creuzot-Garcher and Vincent Daien},

doi = {10.1111/aos.70251},

issn = {1755-3768},

year  = {2026},

date = {2026-00-00},

urldate = {2026-00-00},

journal = {Acta Ophthalmologica},

keywords = {Acta Ophthalmologica, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Sánchez‐Monroy2022,

title = {Subretinal fluid may protect against macular atrophy in neovascular age‐related macular degeneration: 5 years of follow‐up from Fight Retinal Blindness registry},

author = {Jorge Sánchez‐Monroy and Vuong Nguyen and Martin Puzo and Pilar Calvo and Carolina Arruabarrena and Pietro Monaco and Michael Chilov and David Keegan and Daniel Barthelmes and Mark Gillies},

doi = {10.1111/aos.15309},

issn = {1755-3768},

year  = {2023},

date = {2023-06-00},

journal = {Acta Ophthalmologica},

volume = {101},

number = {4},

pages = {457–464},

publisher = {Wiley},

abstract = {Purpose The purpose of the study was to assess the association of macular atrophy (MA) according to the activity of macular neovascularization (MNV) (inactive, only subretinal fluid [SRFL], or active, i.e. including intraretinal fluid [IRFL]) using optical coherence tomography (OCT) in patients with neovascular age‐related macular degeneration (nAMD). Methods Multicentric observational study. Treatment‐naïve nAMD eyes without subfoveal MA or subretinal fibrosis (SF) at baseline were included since 1st January 2010 and 30th September 2016 to allow up to 5 years of treatment follow‐up. Eyes were grouped based on their predominant activity status as: (1) mostly inactive , (2) mostly active non‐SRFL only [IRFL] or (3) mostly active‐SRFL only [onlySRFL] . Kaplan–Meier survival curves estimated the time to development of MA or SF. Cox proportional hazards models evaluated predictors of developing subfoveal MA or SF. The main outcome measure was the risk of developing MA according to predominant MNV activity. Results A total of 973 eyes were eligible for analysis. OnlySRFL eyes had lower risk of developing subfoveal MA (HR [95% CI]: 0.56 [0.36, 0.88]; p = 0.024) and extrafoveal MA (HR [95% CI]: 0.41 [0.27, 0.61]; p < 0.001) than IRFL eyes. IRFL eyes had lower visual acuity (VA) (54.5 letters) and the highest proportion of eyes with vision ≤35 letters (25%) at 5 years while onlySRFL eyes had comparable 5‐year VA (63.7 letters) to inactive eyes (63.7 letters). Conclusion Subretinal fluid appears to protect against MA. Distinguishing the compartment of retinal fluid and understanding its relationship with MA and SF can guide the management of nAMD.},

keywords = {Acta Ophthalmologica, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Gabrielle2022,

title = {Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age‐related macular degeneration in daily clinical practice: data from the FRB! registry},

author = {Pierre‐Henry Gabrielle and Samuel Maitrias and Vuong Nguyen and Jennifer J Arnold and David Squirrell and Louis Arnould and Jorge Sanchez‐Monroy and Francesco Viola and Louise O'Toole and Daniel Barthelmes and Catherine Creuzot‐Garcher and Mark Gillies and},

doi = {10.1111/aos.15137},

issn = {1755-3768},

year  = {2022},

date = {2022-12-00},

journal = {Acta Ophthalmologica},

volume = {100},

number = {8},

publisher = {Wiley},

abstract = {Purpose The main purpose of the study was to report the estimated incidence, cumulative rate, risk factors and outcomes of submacular haemorrhage (SMH) with loss of vision in neovascular age‐related macular degeneration (nAMD) receiving intravitreal injections (IVT) of vascular endothelial growth factor (VEGF) inhibitor in routine clinical practice. Methods Retrospective analysis of treatment‐naïve eyes receiving IVTs of VEGF inhibitors (ranibizumab, aflibercept or bevacizumab) for nAMD from 1 January 2010 to 31 December 2020 that were tracked the Fight Retinal Blindness! registry. Estimated incidence, cumulative rate and hazard ratios (HR) of SMH with loss of vision during treatment were measured using the Poisson regression, Kaplan–Meier survival curves and Cox proportional hazard models. Results We identified 7642 eyes (6425 patients) with a total of 135 095 IVT over a 10‐year period. One hundred five eyes developed SMH with loss of vision with a rate of 1 per 1283 injections (0.08% 95% confidence interval [95% CI] [0.06; 0.09]). The estimated incidence [95% CI] was 4.6 [3.8; 5.7] SMH with loss of vision per year per 1000 treated patients during the study. The cumulative [95% CI] rate of SMH per patient did not increase significantly with each successive injection (p = 0.947). SMH cases had a mean VA drop of around 6 lines at diagnosis, which then improved moderately to a 4‐line loss at 1 year. Conclusions Submacular haemorrhage (SMH) with loss of vision is an uncommon complication that can occur at any time in eyes treated for nAMD in routine clinical practice, with only limited recovery of vision 1 year later.},

keywords = {Acta Ophthalmologica, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Niedzwiecki2021,

title = {12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry},

author = {Mateusz Niedzwiecki and Adrian Hunt and Vuong Nguyen and Hemal Mehta and Catherine Creuzot‐Garcher and Pierre‐Henry Gabrielle and Martin Guillemin and Samantha Fraser‐Bell and Jennifer Arnold and Ian L. McAllister and Mark Gillies and Daniel Barthelmes},

doi = {10.1111/aos.15014},

issn = {1755-3768},

year  = {2022},

date = {2022-06-00},

journal = {Acta Ophthalmologica},

volume = {100},

number = {4},

publisher = {Wiley},

abstract = {Purpose To compare 12‐month treatment outcomes of eyes receiving aflibercept or ranibizumab for macular oedema secondary to central retinal vein occlusion (CRVO) in routine clinical practice. Methods 296 treatment‐naïve eyes receiving either aflibercept (171 eyes, 2 mg) or ranibizumab (125 eyes, 0.5 mg) for macular oedema secondary to CRVO were recruited retrospectively from centres using the prospectively designed FRB! registry. The primary outcome measure was the mean change in LogMAR letter scores of visual acuity (VA). Secondary outcomes included change in central subfield thickness (CST), injections and visits, time to first grading of inactivity, switching and non‐completion from baseline to 12 months. Results Baseline VA (SD) was somewhat better in aflibercept‐ versus ranibizumab‐treated eyes (42.5 ± 25.5 letters versus 36.9 ± 26 letters; p = 0.07) with similar CST (614 (240) μm versus 616 (234) μm: p = 0.95). The 12‐month adjusted mean (95%CI) VA change was +16.6 (12.9, 20.4) letters for aflibercept versus +9.8 (5.5, 14.1) letters for ranibizumab (p = 0.001). The mean (95%CI) adjusted change in CST was significantly greater in aflibercept‐ versus ranibizumab‐treated eyes: −304 (−276, −333) µm versus −252 (−220, −282) µm (p < 0.001). Both groups had a median (Q1, Q3) of 7 (5, 9) injections and 10 (8,13) visits. Aflibercept‐treated eyes became inactive sooner than ranibizumab (p = 0.02). Switching occurred more commonly from ranibizumab (26 eyes, 21%) than from aflibercept (9 eyes, 5%) (p < 0.001). Conclusion Both aflibercept and ranibizumab improved VA and reduced CST in eyes with CRVO in routine clinical practice, with aflibercept showing significantly greater improvements in this comparative analysis.},

keywords = {Acta Ophthalmologica, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Gabrielle2020,

title = {Initial observation or treatment for diabetic macular oedema with good visual acuity: two‐year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry},

author = {Pierre‐Henry Gabrielle and Vuong Nguyen and Sanjeeb Bhandari and Hemal Mehta and Francesco Viola and Jennifer Arnold and Samantha Fraser‐Bell and Daniel Barthelmes and Catherine Creuzot‐Garcher and Mark Gillies},

doi = {10.1111/aos.14672},

issn = {1755-3768},

year  = {2022},

date = {2022-05-00},

journal = {Acta Ophthalmologica},

volume = {100},

number = {3},

pages = {285–294},

publisher = {Wiley},

abstract = {Purpose To compare visual acuity (VA) change at 24 months in eyes with clinically significant DME (CSDME) and good VA initially treated versus initially observed in routine clinical practice. Methods Retrospective analysis of treatment‐naïve eyes with CSDME and good VA (baseline VA ≥ 79 letters), with at least 24 months of follow‐up and initially managed with treatment (intravitreal treatment and/or macular laser) or observation with possible treatment after 4 months that were tracked in a prospectively designed observational registry. Results We identified 150 eligible eyes (98 initially observed, 52 initially treated) of 130 patients. The proportion of eyes with at least a 5‐letter VA loss at 24 months was not significantly different between the groups: 65% with initial observation and 42% with initial treatment (p = 0.39). However, initially observed eyes were more likely to have a 10‐letter VA loss at 24 months (OR = 4.6},

keywords = {Acta Ophthalmologica, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Gabrielle2021,

title = {Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2‐year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry},

author = {Pierre‐Henry Gabrielle and Vuong Nguyen and Catherine Creuzot‐Garcher and Lucia Miguel and Socorro Alforja and Laura Sararols and Ricardo P. Casaroli‐Marano and Javier Zarranz‐Ventura and Mark Gillies and Jennifer Arnold and Daniel Barthelmes},

doi = {10.1111/aos.14893},

issn = {1755-3768},

year  = {2022},

date = {2022-02-00},

journal = {Acta Ophthalmologica},

volume = {100},

number = {1},

publisher = {Wiley},

abstract = {Purpose To report the 24‐month outcomes of vascular endothelial growth factor (VEGF) inhibitors for myopic choroidal neovascularization (mCNV) in predominantly Caucasian eyes in routine clinical practice. Methods Retrospective analysis of treatment‐naïve eyes starting intravitreal injection of VEGF inhibitors of either bevacizumab (1.25 mg) or ranibizumab (0.5 mg) for mCNV from 1 January 2006 to 31 May 2018 that were tracked in the Fight Retinal Blindness! registry. Results We identified 203 eyes (bevacizumab–85 and ranibizumab–118) of 189 patients. The estimated mean (95% CI) change in VA over 24 months for all eyes using longitudinal models was +8 (5, 11) letters with a median (Q1, Q3) of 3 (2, 5) injections given mostly during the first year. The estimated mean change in VA at 24 months was similar between bevacizumab and ranibizumab [+9 (5, 13) letters for bevacizumab versus +9 (6, 13) letters for ranibizumab; p = 0.37]. Both agents were also similar in the mCNV activity outcomes, treatment frequency and visit frequency. Conclusions The 24‐month treatment outcomes of VEGF inhibitors for mCNV were favourable in this largest series yet reported of predominantly Caucasian eyes in routine clinical practice, with approximately two lines of visual gain and a median of three injections given mostly during the first year. These outcomes are similar to those reported for predominantly Asian eyes. Bevacizumab appeared to be as safe and effective as ranibizumab.},

keywords = {Acta Ophthalmologica, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Verbraak2020,

title = {Real‐world treatment outcomes of neovascular Age‐related Macular Degeneration in the Netherlands},

author = {Frank D. Verbraak and Dirk L. Ponsioen and Odette A. M. Tigchelaar‐Besling and Vuong Nguyen and Mark C. Gillies and Daniel Barthelmes and Caroline C. W. Klaver},

doi = {10.1111/aos.14712},

issn = {1755-3768},

year  = {2021},

date = {2021-09-00},

journal = {Acta Ophthalmologica},

volume = {99},

number = {6},

publisher = {Wiley},

abstract = {Purpose To compare treatment outcomes of treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD) with bevacizumab as the first‐line treatment, according to the guidelines of the Dutch Ophthalmological Society, with those treated first with either ranibizumab or aflibercept, as used in many other countries, all treated using a treat‐and‐extend strategy. Methods Data were obtained from the prospectively designed Fight Retinal Blindness! outcomes registry. The primary outcome was the mean change from baseline in visual acuity of all treated eyes, after 12, 24 and 36 months of treatment. Secondary outcomes were the number of injections, the number of visits and the rate of switching to a second anti‐VEGF drug. Results The study included 703 treatment‐naïve eyes with nAMD with 12 months follow‐up, 373 eyes with 24 months follow‐up, and 171 eyes with 36 months follow‐up in the Netherlands, and 1131, 652, and 303 treatment‐naïve eyes with respectively 12, 24, and 36 months of follow‐up in all other countries. The change in visual acuity from baseline did not differ between the Netherlands and the other countries at any follow‐up time. The median number of injections, visits and the proportion of eyes switching treatment was significantly higher in the Netherlands than in the other countries. Conclusion Starting anti‐VEGF treatment for nAMD with bevacizumab, as is mandatory in the Netherlands, delivers outcomes similar to those starting treatment with either ranibizumab or aflibercept, but at a cost of more frequent injections, and visits, and more frequent switching treatment to a second drug.},

keywords = {Acta Ophthalmologica, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Vaze2014,

title = {Consequences of long‐term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age‐related macular degeneration},

author = {Anagha Vaze and Samantha Fraser‐Bell and Mark Gillies},

doi = {10.1111/aos.12417},

issn = {1755-3768},

year  = {2014},

date = {2014-12-00},

journal = {Acta Ophthalmologica},

volume = {92},

number = {8},

publisher = {Wiley},

keywords = {Acta Ophthalmologica, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}